证券代码：301393 证券简称：昊帆生物 公告编号：2024-002 苏州昊帆生物股份有限公司 关于相关股东延长股份锁定期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司首次公开发行股票的情况 经中国证券监督管理委员会核发的《关于同意苏州昊帆生物股份有限公司首 次公开发行股票注册的批复》（证监许可[2023]806 号）同意注册，并经深圳证券 交易所同意，苏州昊帆生物股份有限公司（以下简称"公司"）首次公开发行人 民币普通股（A 股）2,700.00 万股，每股发行价格为 67.68 元，并于 2023 年 7 月 12 日在深圳证券交易所创业板上市交易。 二、相关股东关于股份锁定期的承诺 相关股东在《首次公开发行股票并在创业板上市招股说明书》与《首次公开 发行股票并在创业板上市之上市公告书》中所作相关承诺如下： （一）公司控股股东、实际控制人朱勇承诺 1、自公司股票上市之日起 36 个月内，不转让或者委托他人管理本人直接或 间接持有的公司首次公开发行前股份，也不由公司回购该部分股份； 2、公司股票上市后 6 个月内，若公司股票价格连续 20 ...

民生证券股份有限公司 关于苏州昊帆生物股份有限公司 相关股东延长股份锁定期的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐人"）作为苏州 昊帆生物股份有限公司（以下简称"昊帆生物"或"公司"）首次公开发行股 票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等规定，对昊帆生物相关股东延长股份锁定期的事项进行 了审慎核查，具体情况如下： 一、公司首次公开发行股票的情况 经中国证券监督管理委员会核发的《关于同意苏州昊帆生物股份有限公司 首次公开发行股票注册的批复》（证监许可【2023】806 号）同意注册，并经深 圳证券交易所同意，昊帆生物首次公开发行人民币普通股（A 股）2,700.00 万股， 每股发行价格为 67.68 元，并于 2023 年 7 月 12 日在深圳证券交易所创业板上市 交易。 二、相关股东关于股份锁定期的承诺 相关股东在《首次公开发行股票并在创业板上市招股说明书》与《首次公 开发行股票并在 ...

证券代码：301393 证券简称：昊帆生物 公告编号：2024-001 苏州昊帆生物股份有限公司 首次公开发行网下配售限售股上市流通提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次上市流通的限售股份为苏州昊帆生物股份有限公司（以下简称"公 司"或"昊帆生物"）首次公开发行网下配售限售股。本次解除限售的股东户数 为 7,165 户，股份数量为 1,332,798 股，占公司总股本的 1.23%，限售期为自公司 首次公开发行股票并上市之日起 6 个月。 2、本次解除限售股份的上市流通日期为 2024 年 1 月 12 日（星期五）。 一、首次公开发行网下配售股份概况 经中国证券监督管理委员会《关于同意苏州昊帆生物股份有限公司首次公开 发行股票注册的批复》（证监许可[2023]806 号）同意注册，并经深圳证券交易所 同意，公司首次公开发行 2,700.00 万股人民币普通股（A 股），于 2023 年 7 月 12 日在深圳证券交易所创业板上市交易。首次公开发行前公司总股本为 81,000,000 股，首次公开发行股票完成后公司总股 ...

民生证券股份有限公司 关于苏州昊帆生物股份有限公司 首次公开发行网下配售限售股上市流通的核查意见 经中国证券监督管理委员会《关于同意苏州昊帆生物股份有限公司首次公 开发行股票注册的批复》（证监许可[2023]806 号）同意注册，并经深圳证券交 易所同意，公司首次公开发行 2,700.00 万股人民币普通股（A 股），于 2023 年 7 月 12 日在深圳证券交易所创业板上市交易。首次公开发行前公司总股本为 81,000,000 股，首次公开发行股票完成后公司总股本为 108,000,000 股，其中无 限售条件流通股数量为 23,394,744 股，占本次发行后总股本的比例为 21.66%， 有限售条件股份数量 84,605,256 股（其中：网下配售限售股 1,332,798 股，首发 前限售股 81,000,000 股，战略配售限售股 2,272,458 股），占发行后总股本的比 例为 78.34%。 本次上市流通的限售股属于首次公开发行网下配售限售股，限售期为自公 司首次公开发行并上市之日起 6 个月，股份数量为 1,332,798 股，占公司总股本 的 1.23%，该部分限售股将于 2024 年 ...

民生证券股份有限公司 关于苏州昊帆生物股份有限公司 2023 年度持续督导培训情况报告 深圳证券交易所： 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，作 为苏州昊帆生物股份有限公司（以下简称"昊帆生物"或"公司"）首次公开发行股 票并在创业板上市的保荐机构，民生证券股份有限公司（以下简称"民生证券"或 "保荐机构"）对昊帆生物进行了 2023 年度持续督导培训。现将培训情况报告如下： 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》《深圳证券交易所股票上市规则》等法律法规要求，对上市公司董事、监事、高级 管理人员、中层以上管理人员及上市公司控股股东和实际控制人等相关人员就以下内 容进行了重点培训： （一）上市公司大股东、特定股东的减持规则等； （五）上市公司再融资相关的一般规定和要求。 一、培训基本情况 （一）保荐机构：民生证券股份有限公司 （二）保荐代表人：邵航、刘永泓 （三）培训时间：2023 年 12 月 26 日 （四）培训方式：现场授课 （五）培训地点：昊帆生 ...

民生证券股份有限公司 关于苏州昊帆生物股份有限公司 2023 年度持续督导定期现场检查报告 | 保荐机构名称：民生证券股份有限公司 被保荐公司简称：昊帆生物 | | --- | | 保荐代表人姓名：邵航 联系电话：021-8050 8866 | | 保荐代表人姓名：刘永泓 联系电话：021-8050 8866 | | 现场检查人员姓名：邵航、刘永泓、杨韬、范秀举 | | 现场检查对应期间：2023 年度 | | 现场检查时间：2023 年 12 月 26 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段：查阅公司章程及公司治理等有关文件、查阅历次公司股东大会、 | | 董事会、监事会的会议文件和公告文件；实地查看公司主要管理场所 | | 1.公司章程和公司治理制度是否完备、合规 √ | | 2.公司章程和三会规则是否得到有效执行 √ | | 3.三会会议记录是否完整，时间、地点、出席人员及会 √ | | 议内容等要件是否齐备，会议资料是否保存完整 | | 4.三会会议决议是否由出席会议的相关人员签名确认 √ | | 5.公司董监高是否按照有关法律、行政法 ...

Financial Performance - The company's operating revenue for the current period is CNY 93,536,390.49, representing a 3.63% increase year-over-year [36]. - Net profit attributable to shareholders of the listed company is CNY 20,162,249.25, a decrease of 29.45% compared to the same period last year [36]. - The company reported a total profit of CNY 90,040,392.90 for the current period, compared to CNY 119,525,024.26 in the previous period [36]. - The company experienced a decrease in diluted earnings per share to CNY 0.91, down 28.35% year-over-year [32]. - Basic earnings per share for the current period is CNY 0.20, a decline of 42.86% compared to the previous period [36]. Cash Flow and Assets - As of September 30, 2023, cash and cash equivalents increased by 1,542.31% to CNY 1,631,206,757.39, primarily due to funds received from the initial public offering [16]. - The net cash flow from operating activities for the year-to-date is CNY 42,369,322.17, down 60.95% year-over-year [36]. - Cash and cash equivalents at the end of Q3 2023 totaled CNY 1,631,206,757.39, significantly up from CNY 56,989,236.85 at the end of Q3 2022 [55]. - The company reported a net cash outflow from investing activities of CNY -139,004,598.67, compared to CNY -107,688,257.72 in the previous year [55]. - The company's total current assets amounted to approximately RMB 1,961,912,269.39, a significant increase from RMB 352,669,825.48 in the previous period [24]. - Total assets as of September 30, 2023, amount to CNY 2,274,856,522.25, an increase of 279.11% compared to the end of the previous year [36]. - Total assets as of the end of Q3 2023 were CNY 2,274,856,522.25, compared to CNY 600,048,041.53 at the end of Q3 2022 [50]. Shareholder and Equity Information - The total number of ordinary shareholders reached 17,590, with the largest shareholder holding 47.40% of shares [18]. - The company's equity increased significantly, with total equity now at RMB 1,791,177,029.98, compared to RMB 54,788,300.53 previously [27]. - The equity attributable to shareholders of the listed company is CNY 2,191,247,424.14, up 354.36% from the previous year-end [36]. - The company's total equity attributable to shareholders reached CNY 2,191,247,424.14, a substantial increase from CNY 482,275,952.95 in the previous year [50]. Expenses and Liabilities - Revenue from sales expenses increased by 43.96% to CNY 9,462,994.26, driven by higher personnel costs and travel expenses [17]. - The company reported a 113.67% increase in financial expenses, amounting to CNY -11,069,150.37, due to increased interest from idle funds [17]. - Total liabilities decreased to RMB 83,609,098.11 from RMB 117,772,088.58, reflecting improved financial health [27]. - Deferred tax liabilities rose by 379.96% to CNY 552,712.84, due to changes in the fair value of financial assets [16]. Investments and Development - The company's financial assets increased by 80.70% to CNY 108,417,252.01, attributed to investments in wealth management products using idle funds [16]. - The company has a strategic focus on expanding its market presence and enhancing product offerings, as indicated by ongoing investments in research and development [22]. - Research and development expenses increased to CNY 20,108,005.62, up 22.5% from CNY 16,417,977.59 in Q3 2022 [50]. - The company is actively exploring potential mergers and acquisitions to bolster its market position and drive growth [22]. - The company plans to continue expanding its market presence and investing in new product development [16]. Government Subsidies and Other Income - Other income surged by 143.24% to CNY 3,638,540.83, mainly from increased government subsidies received [17]. - The company recorded a government subsidy of CNY 699,316.47 for the current period [36]. Market Performance - The company successfully completed its initial public offering (IPO) of 27,000,000 shares, with trading commencing on July 12, 2023, increasing total shares to 108,000,000 [22]. - The company has outlined a positive outlook for future performance, driven by increased user engagement and market expansion strategies [22].

证券代码：301393 证券简称：昊帆生物 公告编号：2023-020 苏州昊帆生物股份有限公司 2022 年年度权益分派实施公告 2、自分配方案披露至实施期间，公司股本总额未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配方案及其调整原则一致。 4、本次实施分配方案距离股东大会审议通过的时间未超过两个月。 二、权益分派方案 本公司 2022 年年度权益分派方案为：以公司现有总股本 108,000,000 股为基 数，向全体股东每 10 股派 2.500000 元人民币现金（含税；扣税后，通过深股通 持有股份的香港市场投资者、QFII、RQFII 以及持有首发前限售股的个人和证券 投资基金每 10 股派 2.250000 元；持有首发后限售股、股权激励限售股及无限售 流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所得税，待 个人转让股票时，根据其持股期限计算应纳税额【注】；持有首发后限售股、股 权激励限售股及无限售流通股的证券投资基金所涉红利税，对香港投资者持有基 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司 ...

| （2）发表非同意意见所涉问题及结论意见 | 不适用 | | --- | --- | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 0 次 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8.关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 否 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训次数 | 0 次 | | （2）培训日期 | 不适用 | | （3）培训的主要内容 | 不适用 | | 11.其他需要说明的保荐工作情况 | 无 | 民生证券股份有限公司 关于苏州昊帆生物股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：民生证券股份有限公司 | 被保荐公司简称：昊帆生物 | | --- | --- | | 保荐代表人姓名：邵航 | 联系电话：021-80508866 | | 保荐代表人姓名：刘永泓 | 联系电话：021- ...

Financial Performance - The company's revenue for the reporting period was ¥210,102,576.45, a decrease of 22.29% compared to ¥270,365,516.34 in the same period last year[25]. - Net profit attributable to shareholders was ¥58,737,654.61, down 21.24% from ¥74,580,971.26 year-on-year[25]. - The net profit after deducting non-recurring gains and losses was ¥55,513,823.47, reflecting a decline of 25.43% compared to ¥74,449,200.00 in the previous year[25]. - The net cash flow from operating activities was ¥22,550,452.02, a significant drop of 59.97% from ¥56,338,305.00 in the same period last year[25]. - Basic earnings per share decreased to ¥0.73, down 20.65% from ¥0.92 year-on-year[25]. - Total operating revenue for the first half of 2023 was ¥210,102,576.45, a decrease of 22.3% compared to ¥270,365,516.34 in the first half of 2022[127]. - Total operating costs decreased to ¥144,077,958.80 in the first half of 2023, down 20.9% from ¥182,184,525.03 in the same period last year[127]. - Operating costs accounted for ¥119,682,874.17, which is a reduction of 24.3% from ¥158,170,861.48 in the previous year[127]. - The comprehensive income for the first half of 2023 was ¥58,737,654.61, indicating a positive performance despite the revenue decline[138]. Assets and Liabilities - Total assets increased by 6.35% to ¥638,133,215.49 from ¥600,048,041.53 at the end of the previous year[25]. - Current liabilities decreased to CNY 87,046,704.49 from CNY 109,332,942.60, a reduction of approximately 20.3%[117]. - Total liabilities decreased to CNY 95,992,871.53 from CNY 117,772,088.58, indicating a decline of around 18.5%[117]. - Owner's equity increased to CNY 542,140,343.96 from CNY 482,275,952.95, showing a growth of approximately 12.4%[117]. - Cash and cash equivalents decreased to CNY 22,311,425.09 from CNY 82,172,873.14, a decline of about 72.8%[118]. - Accounts receivable increased significantly to CNY 80,943,948.42 from CNY 44,985,086.97, representing an increase of approximately 80%[118]. - Inventory decreased to CNY 47,872,080.06 from CNY 70,624,057.38, a decline of about 32.3%[118]. - The company reported a significant increase in other receivables, totaling CNY 113,727,230.53 compared to CNY 109,361,810.20, an increase of approximately 4.3%[118]. Market Position and Product Development - The company provides over 160 types of novel and high-quality peptide synthesis reagents, positioning itself as one of the few global companies offering a full range of peptide synthesis reagents[33]. - The market share of the company in the peptide synthesis reagent segment continues to increase, benefiting from the rapid development of downstream industries such as small molecule chemical drugs and peptide drugs[33]. - The company has developed over 60 types of general molecular building blocks, with more than 400 sub-products, indicating a strong product pipeline[33]. - The global market for molecular building blocks is projected to reach 61.2 billion USD by 2024, highlighting significant growth potential for the company's offerings[45]. - The company is actively expanding its product line in high-value, high-barrier specialty products such as liposome and lipid nanoparticle reagents, ionic liquids, PROTAC reagents, and nucleotide reagents[33]. - The company is focusing on the development of liposome and lipid nanoparticle delivery technologies, which have promising applications in various fields including oncology and mRNA vaccines[7]. Research and Development - The company has established a stable R&D team and is focused on attracting talented personnel to maintain its competitive edge in the pharmaceutical sector[63]. - The company is actively pursuing technological advancements and product development to enhance its competitive edge in the market[147]. - The company has faced risks related to insufficient R&D innovation and technological upgrades, which could affect its competitive position in the rapidly evolving pharmaceutical industry[64]. Environmental Compliance - Anhui Haofan has a wastewater treatment facility with a capacity of 120 m³/d, ensuring compliance with wastewater discharge standards[75]. - The company has implemented various measures for air pollution control, including condensation and absorption techniques, with a total air treatment capacity of 66,000 m³/h[75]. - The company is committed to environmental monitoring and has established a self-monitoring plan to ensure compliance with regulatory requirements[76]. - The company has not reported any environmental penalties during the reporting period[77]. Shareholder Information - The company has a total of 81,000,000 shares, all of which are subject to restrictions, representing 100% of the total shares[103]. - The largest shareholder, Zhu Yong, holds 63.20% of the shares, amounting to 51,192,000 shares[106]. - There are no changes in the controlling shareholder or actual controller during the reporting period[109]. Governance and Compliance - The company emphasizes the importance of employee health and safety, conducting regular health check-ups and safety training[79]. - The company has maintained a governance structure that is continuously being improved[77]. - The company has not engaged in any significant related party transactions during the reporting period[85]. - There were no major leasing projects that contributed to over 10% of the total profit during the reporting period[96]. - The company has not experienced any bankruptcy restructuring matters during the reporting period[83]. - The company has not reported any changes in accounting policies or prior period error corrections for the current reporting period[142]. Financial Instruments and Accounting - The financial statements are prepared in accordance with the accounting standards set by the Ministry of Finance, ensuring transparency and accuracy[148]. - Financial instruments include financial assets, financial liabilities, and equity instruments, recognized when the company becomes a party to the relevant financial contract[166]. - The company uses the cost method for long-term equity investments in subsidiaries, recognizing investment income based on declared dividends[192]. - The company evaluates the recoverable amount of inventory based on estimated selling prices minus estimated costs and related taxes[187]. - The company has a policy for recognizing expected credit losses based on forward-looking information[183].